Yang J
Department of Lung Disease, Zhengzhou Traditional Chinese Hospital, Zhengzhou, China.
J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):453-457.
Acute bronchitis is one of the most common diseases in the world. The Suhuang Zhike capsule is a part of Traditional Chinese Medicine (TCM) that was approved to treat acute bronchitis. In order to study the clinical effects of the Suhuang Zhike capsule on acute bronchitis subjects, the clinical data of 96 patients from the Department of Lung Disease of Zhengzhou Traditional Chinese Hospital from June 2014 to June 2014 were retrospectively analyzed. The patients were randomly divided into a control group and a Suhuang Zhike capsule treatment group, each with 48 cases. The therapeutic effects of the treatments were evaluated on the tenth day. The results showed that the total effective rate of the observation group was 95.83%, which was significantly higher when compared with the control group, which was 72.91% (P less than 0.005). The clinical signs (e.g. coughing, itchy throat, dry cough without phlegm, little sputum) of the two groups obviously decreased, and the difference was statistically significant when compared with the pretreatment scores (P less than 0.005). The decreased rate of the observation group was significantly larger when compared with the control group (P less than 0.005). The time it took for the clinical symptoms of the observation group to resolve was significantly shorter when compared with the control group (P less than 0.005). After treatment, the serum levels of c-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-α) of the two groups obviously decreased. There was a significant difference in these serum levels when compared with pre-treatment levels (P less than 0.005). The decreased rate of the observation group was obviously larger when compared with the control group (P less than 0.005). In the observation group, there were 3 cases with adverse reactions (nausea in 2 cases and mild vomiting in 1 case) during the observation period, with an adverse reaction rate of 6.25% In the control group, 10 cases developed adverse reactions (nausea in 2 cases, mild diarrhea in 3 cases, and mild vomiting in 5 cases), with an adverse reaction rate of 20.83% (P less than 0.005, vs the observation group). In this study, we showed that the Suhuang Zhike capsule provides positive therapeutic effects in the treatment of acute bronchitis by promoting the alleviation of the clinical symptoms in a short time and reducing the inflammation in the respiratory tract.
急性支气管炎是世界上最常见的疾病之一。苏黄止咳胶囊是被批准用于治疗急性支气管炎的中药的一部分。为了研究苏黄止咳胶囊对急性支气管炎患者的临床疗效,回顾性分析了郑州市中医院肺病科2014年6月至2014年6月96例患者的临床资料。将患者随机分为对照组和苏黄止咳胶囊治疗组,每组48例。在第10天评估治疗效果。结果显示,观察组总有效率为95.83%,与对照组的72.91%相比显著更高(P<0.005)。两组的临床症状(如咳嗽、咽喉痒、干咳无痰、咳痰少)均明显减轻,与治疗前评分相比差异有统计学意义(P<0.005)。观察组的减轻率与对照组相比显著更大(P<0.005)。观察组临床症状缓解所需时间与对照组相比显著更短(P<0.005)。治疗后,两组的血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和肿瘤坏死因子α(TNF-α)水平均明显降低。与治疗前水平相比,这些血清水平有显著差异(P<0.005)。观察组的降低率与对照组相比明显更大(P<0.005)。观察组在观察期间有3例出现不良反应(2例恶心,1例轻度呕吐),不良反应发生率为6.25%。对照组有10例出现不良反应(2例恶心,3例轻度腹泻,5例轻度呕吐),不良反应发生率为20.83%(与观察组相比,P<0.005)。在本研究中,我们表明苏黄止咳胶囊通过促进临床症状在短时间内缓解并减轻呼吸道炎症,对急性支气管炎的治疗具有积极的疗效。